Lunai Bioworks Inc. (LNAI) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US29350E2037
Lunai Bioworks Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | – | 51,992.00 USD |
| Operating income | -188.97 m USD | -8.70 m USD |
| EBIT | -177.28 m USD | -3.33 m USD |
| Net income | -178.01 m USD | -3.56 m USD |
| Diluted EPS – continuing operations | -1.08 USD | -1.06 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
More stocks
- GPO Plus, Inc. (GPOX)
- Ocean Thermal Energy Corp (CPWR)
- Sirius Media (ALSRS.PA)
- Odyssey Health, Inc. (ODYY)
- AVENUE THERAPEUTICS, INC. (ATXI)
- Catheter Precision, Inc. (VTAK)
- Mentor Capital, Inc. (MNTR)
- ProtoKinetix, Inc. (PKTX)
- Athena Bitcoin Global (ABIT)
- Protagenic Therapeutics, Inc.\new (PTIX)
- Everything Blockchain, Inc. (EBZT)
- My Size, Inc. (MYSZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.